Selected research
Industry Research
Drug-Device Combination Products Industry Research Report 2026
Market perspective
The global Drug-Device Combination Products market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Drug-Device Combination Products market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Drug-Device Combination Products market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Drug-Device Combination Products market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Drug-Device Combination Products include GSK, Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi, Boston Scientific, Abbott, Boehringer Ingelheim and Medtronic, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Drug-Device Combination Products market in terms of revenue (US$ million) and, where applicable, service volume (Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Drug-Device Combination Products.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Drug-Device Combination Products Market by Company
GSK
Novo Nordisk
Eli Lilly
AstraZeneca
Sanofi
Boston Scientific
Abbott
Boehringer Ingelheim
Medtronic
Mylan
3M
Hisamitsu
Smith & Nephew
Molnlycke
Teleflex
BD
Lepu Medical
MicroPort
Terumo
B. Braun
Antares Pharma
Drug-Device Combination Products Segment by Type
Drug-Coated Device
Prefilled Drug Delivery Systems
Nebulizer and Inhaler
Transdermal Delivery System
Others
Drug-Device Combination Products Segment by Application
Hospital andClinic
Retail Pharmacies
Other
Drug-Device Combination Products Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drug-Device Combination Products market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Drug-Device Combination Products and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drug-Device Combination Products.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Drug-Device Combination Products companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Drug-Coated Device
- Prefilled Drug Delivery Systems
- Nebulizer and Inhaler
- Transdermal Delivery System
- Others
Applications
- Hospital andClinic
- Retail Pharmacies
- Other
Companies covered
- GSK
- Novo Nordisk
- Eli Lilly
- AstraZeneca
- Sanofi
- Boston Scientific
- Abbott
- Boehringer Ingelheim
- Medtronic
- Mylan
- 3M
- Hisamitsu
- Smith & Nephew
- Molnlycke
- Teleflex
- BD
- Lepu Medical
- MicroPort
- Terumo
- B. Braun
- Antares Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Drug-Device Combination Products by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Drug-Coated Device
- 2.2.3 Prefilled Drug Delivery Systems
- 2.2.4 Nebulizer and Inhaler
- 2.2.5 Transdermal Delivery System
- 2.2.6 Others
- 2.3 Drug-Device Combination Products by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital andClinic
- 2.3.3 Retail Pharmacies
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Drug-Device Combination Products Breakdown Data by Type
- 3.1 Global Drug-Device Combination Products Historic Market Size by Type (2021-2026)
- 3.2 Global Drug-Device Combination Products Forecasted Market Size by Type (2027-2032)
4 Drug-Device Combination Products Breakdown Data by Application
- 4.1 Global Drug-Device Combination Products Historic Market Size by Application (2021-2026)
- 4.2 Global Drug-Device Combination Products Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Drug-Device Combination Products Market Perspective (2021-2032)
- 5.2 Global Drug-Device Combination Products Growth Trends by Region
- 5.2.1 Global Drug-Device Combination Products Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Drug-Device Combination Products Historic Market Size by Region (2021-2026)
- 5.2.3 Drug-Device Combination Products Forecasted Market Size by Region (2027-2032)
- 5.3 Drug-Device Combination Products Market Dynamics
- 5.3.1 Drug-Device Combination Products Industry Trends
- 5.3.2 Drug-Device Combination Products Market Drivers
- 5.3.3 Drug-Device Combination Products Market Challenges
- 5.3.4 Drug-Device Combination Products Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Drug-Device Combination Products Players by Revenue
- 6.1.1 Global Top Drug-Device Combination Products Players by Revenue (2021-2026)
- 6.1.2 Global Drug-Device Combination Products Revenue Market Share by Players (2021-2026)
- 6.2 Global Drug-Device Combination Products Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Drug-Device Combination Products Head Office and Area Served
- 6.4 Global Drug-Device Combination Products Players, Product Type & Application
- 6.5 Global Drug-Device Combination Products Manufacturers Established Date
- 6.6 Global Drug-Device Combination Products Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Drug-Device Combination Products Market Size (2021-2032)
- 7.2 North America Drug-Device Combination Products Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Drug-Device Combination Products Market Size by Country (2021-2026)
- 7.4 North America Drug-Device Combination Products Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Drug-Device Combination Products Market Size (2021-2032)
- 8.2 Europe Drug-Device Combination Products Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Drug-Device Combination Products Market Size by Country (2021-2026)
- 8.4 Europe Drug-Device Combination Products Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Drug-Device Combination Products Market Size (2021-2032)
- 9.2 Asia-Pacific Drug-Device Combination Products Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Drug-Device Combination Products Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Drug-Device Combination Products Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Drug-Device Combination Products Market Size (2021-2032)
- 10.2 South America Drug-Device Combination Products Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Drug-Device Combination Products Market Size by Country (2021-2026)
- 10.4 South America Drug-Device Combination Products Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Drug-Device Combination Products Market Size (2021-2032)
- 11.2 Middle East & Africa Drug-Device Combination Products Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Drug-Device Combination Products Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Drug-Device Combination Products Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 GSK
- 12.1.1 GSK Company Information
- 12.1.2 GSK Business Overview
- 12.1.3 GSK Revenue in Drug-Device Combination Products Business (2021-2026)
- 12.1.4 GSK Drug-Device Combination Products Product Portfolio
- 12.1.5 GSK Recent Developments
- 12.2 Novo Nordisk
- 12.2.1 Novo Nordisk Company Information
- 12.2.2 Novo Nordisk Business Overview
- 12.2.3 Novo Nordisk Revenue in Drug-Device Combination Products Business (2021-2026)
- 12.2.4 Novo Nordisk Drug-Device Combination Products Product Portfolio
- 12.2.5 Novo Nordisk Recent Developments
- 12.3 Eli Lilly
- 12.3.1 Eli Lilly Company Information
- 12.3.2 Eli Lilly Business Overview
- 12.3.3 Eli Lilly Revenue in Drug-Device Combination Products Business (2021-2026)
- 12.3.4 Eli Lilly Drug-Device Combination Products Product Portfolio
- 12.3.5 Eli Lilly Recent Developments
- 12.4 AstraZeneca
- 12.4.1 AstraZeneca Company Information
- 12.4.2 AstraZeneca Business Overview
- 12.4.3 AstraZeneca Revenue in Drug-Device Combination Products Business (2021-2026)
- 12.4.4 AstraZeneca Drug-Device Combination Products Product Portfolio
- 12.4.5 AstraZeneca Recent Developments
- 12.5 Sanofi
- 12.5.1 Sanofi Company Information
- 12.5.2 Sanofi Business Overview
- 12.5.3 Sanofi Revenue in Drug-Device Combination Products Business (2021-2026)
- 12.5.4 Sanofi Drug-Device Combination Products Product Portfolio
- 12.5.5 Sanofi Recent Developments
- 12.6 Boston Scientific
- 12.6.1 Boston Scientific Company Information
- 12.6.2 Boston Scientific Business Overview
- 12.6.3 Boston Scientific Revenue in Drug-Device Combination Products Business (2021-2026)
- 12.6.4 Boston Scientific Drug-Device Combination Products Product Portfolio
- 12.6.5 Boston Scientific Recent Developments
- 12.7 Abbott
- 12.7.1 Abbott Company Information
- 12.7.2 Abbott Business Overview
- 12.7.3 Abbott Revenue in Drug-Device Combination Products Business (2021-2026)
- 12.7.4 Abbott Drug-Device Combination Products Product Portfolio
- 12.7.5 Abbott Recent Developments
- 12.8 Boehringer Ingelheim
- 12.8.1 Boehringer Ingelheim Company Information
- 12.8.2 Boehringer Ingelheim Business Overview
- 12.8.3 Boehringer Ingelheim Revenue in Drug-Device Combination Products Business (2021-2026)
- 12.8.4 Boehringer Ingelheim Drug-Device Combination Products Product Portfolio
- 12.8.5 Boehringer Ingelheim Recent Developments
- 12.9 Medtronic
- 12.9.1 Medtronic Company Information
- 12.9.2 Medtronic Business Overview
- 12.9.3 Medtronic Revenue in Drug-Device Combination Products Business (2021-2026)
- 12.9.4 Medtronic Drug-Device Combination Products Product Portfolio
- 12.9.5 Medtronic Recent Developments
- 12.10 Mylan
- 12.10.1 Mylan Company Information
- 12.10.2 Mylan Business Overview
- 12.10.3 Mylan Revenue in Drug-Device Combination Products Business (2021-2026)
- 12.10.4 Mylan Drug-Device Combination Products Product Portfolio
- 12.10.5 Mylan Recent Developments
- 12.11 3M
- 12.11.1 3M Company Information
- 12.11.2 3M Business Overview
- 12.11.3 3M Revenue in Drug-Device Combination Products Business (2021-2026)
- 12.11.4 3M Drug-Device Combination Products Product Portfolio
- 12.11.5 3M Recent Developments
- 12.12 Hisamitsu
- 12.12.1 Hisamitsu Company Information
- 12.12.2 Hisamitsu Business Overview
- 12.12.3 Hisamitsu Revenue in Drug-Device Combination Products Business (2021-2026)
- 12.12.4 Hisamitsu Drug-Device Combination Products Product Portfolio
- 12.12.5 Hisamitsu Recent Developments
- 12.13 Smith & Nephew
- 12.13.1 Smith & Nephew Company Information
- 12.13.2 Smith & Nephew Business Overview
- 12.13.3 Smith & Nephew Revenue in Drug-Device Combination Products Business (2021-2026)
- 12.13.4 Smith & Nephew Drug-Device Combination Products Product Portfolio
- 12.13.5 Smith & Nephew Recent Developments
- 12.14 Molnlycke
- 12.14.1 Molnlycke Company Information
- 12.14.2 Molnlycke Business Overview
- 12.14.3 Molnlycke Revenue in Drug-Device Combination Products Business (2021-2026)
- 12.14.4 Molnlycke Drug-Device Combination Products Product Portfolio
- 12.14.5 Molnlycke Recent Developments
- 12.15 Teleflex
- 12.15.1 Teleflex Company Information
- 12.15.2 Teleflex Business Overview
- 12.15.3 Teleflex Revenue in Drug-Device Combination Products Business (2021-2026)
- 12.15.4 Teleflex Drug-Device Combination Products Product Portfolio
- 12.15.5 Teleflex Recent Developments
- 12.16 BD
- 12.16.1 BD Company Information
- 12.16.2 BD Business Overview
- 12.16.3 BD Revenue in Drug-Device Combination Products Business (2021-2026)
- 12.16.4 BD Drug-Device Combination Products Product Portfolio
- 12.16.5 BD Recent Developments
- 12.17 Lepu Medical
- 12.17.1 Lepu Medical Company Information
- 12.17.2 Lepu Medical Business Overview
- 12.17.3 Lepu Medical Revenue in Drug-Device Combination Products Business (2021-2026)
- 12.17.4 Lepu Medical Drug-Device Combination Products Product Portfolio
- 12.17.5 Lepu Medical Recent Developments
- 12.18 MicroPort
- 12.18.1 MicroPort Company Information
- 12.18.2 MicroPort Business Overview
- 12.18.3 MicroPort Revenue in Drug-Device Combination Products Business (2021-2026)
- 12.18.4 MicroPort Drug-Device Combination Products Product Portfolio
- 12.18.5 MicroPort Recent Developments
- 12.19 Terumo
- 12.19.1 Terumo Company Information
- 12.19.2 Terumo Business Overview
- 12.19.3 Terumo Revenue in Drug-Device Combination Products Business (2021-2026)
- 12.19.4 Terumo Drug-Device Combination Products Product Portfolio
- 12.19.5 Terumo Recent Developments
- 12.20 B. Braun
- 12.20.1 B. Braun Company Information
- 12.20.2 B. Braun Business Overview
- 12.20.3 B. Braun Revenue in Drug-Device Combination Products Business (2021-2026)
- 12.20.4 B. Braun Drug-Device Combination Products Product Portfolio
- 12.20.5 B. Braun Recent Developments
- 12.21 Antares Pharma
- 12.21.1 Antares Pharma Company Information
- 12.21.2 Antares Pharma Business Overview
- 12.21.3 Antares Pharma Revenue in Drug-Device Combination Products Business (2021-2026)
- 12.21.4 Antares Pharma Drug-Device Combination Products Product Portfolio
- 12.21.5 Antares Pharma Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst